These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28343354)

  • 1. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
    Wijnsma KL; Schijvens AM; Rossen JWA; Kooistra-Smid AMDM; Schreuder MF; van de Kar NCAJ
    Pediatr Nephrol; 2017 Jul; 32(7):1263-1268. PubMed ID: 28343354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.
    Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C
    Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).
    Caillaud C; Zaloszyc A; Licht C; Pichault V; Frémeaux-Bacchi V; Fischbach M
    Pediatr Nephrol; 2016 Jan; 31(1):157-61. PubMed ID: 26399238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotypes and virulence profiles of Shiga toxin-producing Escherichia coli strains isolated during 2017 from human infections in Switzerland.
    Nüesch-Inderbinen M; Morach M; Cernela N; Althaus D; Jost M; Mäusezahl M; Bloomberg G; Stephan R
    Int J Med Microbiol; 2018 Oct; 308(7):933-939. PubMed ID: 30042042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Genomics of Shiga Toxin-Producing Escherichia coli Strains Isolated from Pediatric Patients with and without Hemolytic Uremic Syndrome from 2000 to 2016 in Finland.
    Bai X; Ylinen E; Zhang J; Salmenlinna S; Halkilahti J; Saxen H; Narayanan A; Jahnukainen T; Matussek A
    Microbiol Spectr; 2022 Aug; 10(4):e0066022. PubMed ID: 35730965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.
    Ardissino G; Possenti I; Vignati C; Daprai L; Capone V; Brigotti M; Luini MV; Consonni D; Montini G
    Pediatr Nephrol; 2020 Oct; 35(10):1997-2001. PubMed ID: 32734345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide association study of hemolytic uremic syndrome causing Shiga toxin-producing Escherichia coli from Sweden, 1994-2018.
    Matussek A; Mernelius S; Chromek M; Zhang J; Frykman A; Hansson S; Georgieva V; Xiong Y; Bai X
    Eur J Clin Microbiol Infect Dis; 2023 Jun; 42(6):771-779. PubMed ID: 37103716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Shiga toxin producing- and enteropathogenic Escherichia coli of the emerging serotype O80:H2 isolated from humans and diarrhoeic calves in Belgium.
    De Rauw K; Thiry D; Caljon B; Saulmont M; Mainil J; Piérard D
    Clin Microbiol Infect; 2019 Jan; 25(1):111.e5-111.e8. PubMed ID: 30076975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing
    Bruyand M; Mariani-Kurkdjian P; Le Hello S; King LA; Van Cauteren D; Lefevre S; Gouali M; Jourdan-da Silva N; Mailles A; Donguy MP; Loukiadis E; Sergentet-Thevenot D; Loirat C; Bonacorsi S; Weill FX; De Valk H;
    Euro Surveill; 2019 Feb; 24(8):. PubMed ID: 30808442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
    Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C
    Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland.
    Rastawicki W; Śmietańska K; Rokosz-Chudziak N; Wołkowicz T
    Lett Appl Microbiol; 2020 Jun; 70(6):440-446. PubMed ID: 32270510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of O157 versus non-O157 Shiga toxin-producing Escherichia coli infections in Minnesota, 2000-2006.
    Hedican EB; Medus C; Besser JM; Juni BA; Koziol B; Taylor C; Smith KE
    Clin Infect Dis; 2009 Aug; 49(3):358-64. PubMed ID: 19548834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative genomic analysis of a Shiga toxin-producing Escherichia coli (STEC) O145:H25 associated with a severe pediatric case of hemolytic uremic syndrome in Davidson County, Tennessee, US.
    Guerra JA; Zhang C; Bard JE; Yergeau D; Halasa N; Gómez-Duarte OG
    BMC Genomics; 2020 Aug; 21(1):564. PubMed ID: 32807093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M
    Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996-2006.
    Espié E; Grimont F; Mariani-Kurkdjian P; Bouvet P; Haeghebaert S; Filliol I; Loirat C; Decludt B; Minh NN; Vaillant V; de Valk H
    Pediatr Infect Dis J; 2008 Jul; 27(7):595-601. PubMed ID: 18520972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serogroup-specific bacterial engineered glycoproteins as novel antigenic targets for diagnosis of shiga toxin-producing-escherichia coli-associated hemolytic-uremic syndrome.
    Melli LJ; Ciocchini AE; Caillava AJ; Vozza N; Chinen I; Rivas M; Feldman MF; Ugalde JE; Comerci DJ
    J Clin Microbiol; 2015 Feb; 53(2):528-38. PubMed ID: 25472487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-genome characterization of hemolytic uremic syndrome-causing Shiga toxin-producing
    Hua Y; Chromek M; Frykman A; Jernberg C; Georgieva V; Hansson S; Zhang J; Marits AK; Wan C; Matussek A; Bai X
    Virulence; 2021 Dec; 12(1):1296-1305. PubMed ID: 33939581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glyco-iELISA: a highly sensitive and unambiguous serological method to diagnose STEC-HUS caused by serotype O157.
    Wijnsma KL; Veissi ST; van Bommel SAM; Heuver R; Volokhina EB; Comerci DJ; Ugalde JE; van de Kar NCAJ; van den Heuvel LPWJ
    Pediatr Nephrol; 2019 Apr; 34(4):631-639. PubMed ID: 30367236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.